SOLV Solventum Corp.

Solventum, a 3M spinoff, overcame initial investor unrest in 2025 by selling its purification and filtration business for $4 billion and acquiring Acera Surgical for $850 million. These strategic moves allowed the company to pay down debt, streamline its portfolio, and attract renewed investor confidence, leading to a significant turnaround in its financial performance and stock price. CEO Bryan Hanson's focus on efficiency and a decentralized structure has positioned the company for positive momentum in 2026.

Solventum Corporation (NYSE:SOLV) has received an average "Hold" recommendation from thirteen brokerages, with an average 12-month price target of $87.00. The company recently authorized a $1.00 billion share buyback and reported strong Q3 earnings, beating analyst estimates. Major institutional investors have also increased their stakes in Solventum, indicating growing confidence in the stock.

This article provides a comprehensive overview of Thermo Fisher Scientific (TMO) stock, covering major news, analyst forecasts, and key catalysts influencing its performance before the market opens on December 26, 2025. It details recent acquisitions, capital return strategies, operational results, product developments, and Wall Street's outlook. The report emphasizes the company's strategic M&A, bioprocessing expansion, and pharma services growth as drivers of its evolving growth profile.

Strong Tower Advisory Services increased its stake in Solventum Corporation (NYSE:SOLV) by 20.5% in the third quarter, acquiring an additional 16,851 shares to now hold 99,169 shares valued at approximately $7.24 million. Solventum recently exceeded quarterly earnings estimates and announced a $1 billion share repurchase plan. The stock currently holds a "Hold" consensus rating from analysts with an average target price of $87.00.

Solventum (NYSE: SOLV) has completed the acquisition of Acera Surgical for an upfront payment of $725 million and up to $125 million in contingent cash payments. This strategic acquisition expands Solventum's MedSurg portfolio into synthetic tissue matrices for regenerative wound care and is expected to be accretive to adjusted EPS beginning in 2027. The deal is part of Solventum's three-phased transformation plan to accelerate growth and create value for patients, clinicians, and shareholders.

This article provides live stock price data, charts, and news for Solventum Corp. (SOLV). It includes financial details such as market capitalization, PE ratio, dividend yield, historical returns, balance sheet data, income statements, and cash flow information. The company, based in Saint Paul, Minnesota, is a healthcare firm focused on developing innovative solutions for the healthcare sector.